Boston-based company Acceleron Pharma specializes in developing protein therapeutics for cancer and rare diseases. The company's products in development include sotatercept and ACE-536, both in Phase II clinical trials. They aim to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes, as well as red blood cell disorders. Acceleron's dalantercept is also in Phase II clinical trials, with the goal of inhibiting blood vessel formation in tumors through the use of vascular endothelial growth factor pathway inhibitors.
Acceleron Pharma Inc.'s ticker is XLRN
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Acceleron Pharma Inc.
It is http://www.acceleronpharma.com/
Acceleron Pharma Inc. is in the Healthcare sector
Acceleron Pharma Inc. is in the Biotechnology industry
The following five companies are Acceleron Pharma Inc.'s industry peers: